Haemophilus b conjugate vaccine: Difference between revisions
| Line 34: | Line 34: | ||
''' [[Haemophilus b conjugate vaccine description|Description]]''' | ''' [[Haemophilus b conjugate vaccine description|Description]]''' | ||
'''| [[Haemophilus b conjugate vaccine clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Haemophilus b conjugate vaccine clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Haemophilus b conjugate vaccine indications and usage|Indications and Usage]]''' | '''| [[Haemophilus b conjugate vaccine indications and usage|Indications and Usage]]''' | ||
'''| [[Haemophilus b conjugate vaccine contraindications|Contraindications]]''' | '''| [[Haemophilus b conjugate vaccine contraindications|Contraindications]]''' | ||
| Line 41: | Line 40: | ||
'''| [[Haemophilus b conjugate vaccine drug interactions|Drug Interactions]]''' | '''| [[Haemophilus b conjugate vaccine drug interactions|Drug Interactions]]''' | ||
'''| [[Haemophilus b conjugate vaccine overdosage|Overdosage]]''' | '''| [[Haemophilus b conjugate vaccine overdosage|Overdosage]]''' | ||
'''| [[Haemophilus b conjugate vaccine dosage and administration|Dosage and Administration]]''' | '''| [[Haemophilus b conjugate vaccine dosage and administration|Dosage and Administration]]''' | ||
'''| [[Haemophilus b conjugate vaccine how supplied|How Supplied]]''' | '''| [[Haemophilus b conjugate vaccine how supplied|How Supplied]]''' | ||
Latest revision as of 14:58, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Haemophilus influenzae type B vaccine (Hib janan or PRP vaccine[1]) is a conjugate vaccine developed for the prevention of invasive disease caused by Haemophilus influenzae type b bacteria. The Centers for Disease Control and Prevention (CDC) has recommended the use of the Hib vaccine.[2] Due to routine use of the Hib vaccine in the U.S. from 1980 to 1990, the incidence of invasive Hib disease has decreased from 40–100 per 100,000 children down to 1.3 per 100,000.[3] Vaccinations against Haemophilus influenzae (Hib) have decreased early childhood meningitis significantly in developed countries and recently in developing countries.[4]
Category
Vaccine
US Brand Names
HIBERIX®
FDA Package Insert
Description | Clinical Pharmacology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Although Hib vaccine is given to children, Hib infections have also decreased in adults. This decrease occurred because of herd immunity; children infected with Hib carry the bacteria in their nasal passages while clearing the infection. These Hib-carrying children would regularly infect adults. The practice of vaccinating children eliminated the source of the bacteria, reducing the rate of Hib in adults.
References
- ↑ PMID 2107520 (PMID 2107520)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ "Recommendation of the Immunization Practices Advisory Committee (ACIP) Polysaccharide Vaccine for Prevention of Haemophilus influenzae Type b Disease". MMWR Weekly. 34 (15): 201–5. 1985-04-19. ISSN 0149-2195. Retrieved 2008-10-03.
- ↑ "Haemophilus influenzae Serotype b (Hib) Disease". Disease Listing. Centers for Disease Control and Prevention. 2008-04-04. Retrieved 2008-10-03.
- ↑ "Deadly Disease Eliminated in Children under Five Years of Age in Uganda" (Press release). GAVI Alliance. 2008-03-10. Retrieved 2008-10-03.